X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

Five key facts about the market for insulins

By Holly Campbell  |    April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...   Read More

The PBM story you haven’t heard: Hidden fees quadrupled in two years

By Robert Zirkelbach  |    March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...   Read More

OptumRX: Sharing rebates with patients is “worth it”

By Holly Campbell  |    March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...   Read More

Event tomorrow: Making the biopharmaceutical supply chain work for patients

By Katie Koziara  |    May 2, 2018
In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...   Read More

Advance price notification: A transparency measure that fails patients

By Saumil Pandya and Emily Donaldson  |    March 29, 2018
Most transparency reforms aim to correct perceived misaligned incentives in the biopharmaceutical marketplace. However, many efforts to mandate information flow in the private market have serious...   Read More

New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed

By Holly Campbell  |    March 27, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could...   Read More

ICYMI – Two PBM reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    March 2, 2018
Newly released pharmacy benefit manager (PBM) data show medicine spending is growing at the slowest rate in years. After accounting for discounts and rebates negotiated with biopharmaceutical...   Read More

Copay coupons can help ease patients’ out-of-pocket costs

By Holly Campbell  |    February 16, 2018
Each year, middlemen, like pharmacy benefit managers (PBMs) and insurers, shift more of the costs of health care to patients. Ensuring patients have affordable access to their medicines is the top...   Read More

Why won’t the insurance industry tell the truth about medicine costs?

By Robert Zirkelbach  |    May 10, 2017
Discussions about the cost of medicines are important. We recognize that many patients are struggling to access the medicines they need, and we want to work with policymakers and other health care...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates